Curriculum vitae (CV)
Prof. Dr. med, Matthias Griese
Physician, Professor of Pediatrics
Head Department of Pediatric Pulmonology
Dr von Hauner Children´s Hospital
Ludwig-Maximilians-University of Munich
Education
Liscensed as Pediatric Pulmonologist 2004
Apl.-Professor of Pediatrics July 2000
Fellowship of the Mukoviscidose e.V. 1995, Centre Hospitaleer Lyon-Sud, France
Liscensed as Neonatologist in 1994
Habilitation 1994 Dr. med. habil., venia legendi Kinderheilkunde
Chief Section of Pulmology and Allergology, Kinderpoliklinik University of Munich
Liscensed as Pediatrician and Allergologist in October 1993
Senior Resident in Pediatrics, Kinderpoliklinik University of Munich 1992- 1993
Senior Resident in Neonatology, Frauenklinik Klinikum Großhadern, University of Munich 1991- 1992
Postdoctoral Fellowship, Dept. Pediatrics, Yale University, New Haven, CT, USA 1989-1991
Research fellow of B. Braun Foundation, Melsungen, Febr. - Okt. 1987
Resident in Pediatrics, University of Düsseldorf 1985 - 1988
United States Medical Licensing Examination: ECFMG passed basic and clinical science component, Jan. 1987
Medical thesis: Department of Physiology, RWTH Aachen (Prof. Kammermeier).
Medical college 1978 - 1980 Basic sciences, University of Bochum 1980 - 1984 Clinical sciences, University of Aachen
Awards
European Respiratory Society (ERS) AWARD FOR RARE PULMONARY DISEASE 2014 in recognition of his outstanding contribution to research in respiratory medicine.
Windorfer Award for excellent clinical study „ Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial“ 2014
Adolf-Windorfer Award for excellent clinical study „Broncho-alveolar Lavage for Evaluation of anti-inflammatory treatment (BEAT)“ 2005
Curt Dehner Award 1996 for Research on bronchopulmonary diseases
Johannes Wenner Award - Society of Pediatric Pneumology 1993
Board activities
President Kids Lung Register Foundation 2009-2018
Board of directors Arbeitsgemeinschaft Ärzte im Mukoviszidose eV 2005-2009
Head board of directors Forschungsgemeinschaft Mukoviszidose (FGM) 2004-2011
Board of directors Society for Pediatric Pneumology 1997 - 2012
Publications
Books
Peer reviewed paper (see pubmed, Griese M)
https://www.ncbi.nlm.nih.gov/pubmed/?term=Griese+M
Special interests
Comprehensive clincial service for children of all age groups suffering from complex lung diseases
Founding and development of a register for rare pediatric lung diseases (kids lung register, Kinderlungenregister)
Molecular pneumology of rare lung diseases
Surfactant system of the lungs
Specialized diagnostics in rare lung diseases
Diseases due to mutations in the gene of the ABCA3 transporter
National Delegates
| Country | Delegate | Lay representative |
| Italy |
Dr. Elisabetta Bignamini, ebignamini@cittadellasalute.to.it |
|
| Italy |
Dr. Nicola Ullmann, This email address is being protected from spambots. You need JavaScript enabled to view it. |
|
| Iran |
Prof. Dr. Mohammad Ashkan Moslehi This email address is being protected from spambots. You need JavaScript enabled to view it. |
|
Projects
Research Projects (2015, ongoing)
| European Management Platform for children´s interstitial lung diseases (chILD-EU) | Kids lung register |
| In vitro modelling of the surfactant transporter ABCA3 defects | DZL 2.0 |
| Molecular genetic diagnosis of rare pediatric lung diseases | DZL 2.0 |
| HCQ4Surf-E-Rare | Erare, BMBF |
| ENTeR-chILD-COST | EU |
Clinical trials (2015, ongoing)
|
2015- RECRUITING
2015 – ongoing
2015 – ongoing
2016 - ongoing |
Hydroxychloroquine in pediatric ILD: START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) EudraCT: 2013-003714-40 NCT02615938 A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis,Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function Vertex Study Number: VX14-661-108 VX-661 IND Number: 108,105 EudraCT Number: 2014-004788-18. NCT02392234 A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and OlderWith Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Vertex Study Number:VX14-661-106, IND Number: 108,105 EudraCT Number: 2014-004837-13, NCT02347657 Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long- term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation Vertex Study Number: VX14-661-110, VX-661 IND Number: 108,105, Ivacaftor IND Number: 74,633 EudraCT Number: 2014-004827-29, 4 NCT02565914 |
|
|
Projects (1999-2015, closed)
| Topic | Funding |
| Großgeräteantrag mit AG Klein; Confokales ZEISS-Lasermikroskop | DFG |
| Chronic tachypnea of infancy; pediatric interstitial lung diseases | DZL 1.0 |
| Israel Kooperationsprojekt on rare lung diseases | Hirmer Stiftung |
| Cells models of the surfactant transporter ABCA3 | DFG-970/8-1 |
| chILD – EU-Projekt: Orphans Unite: chILD better together –? European Management Platform for Childhood Interstitial Lung Diseases. Grant Agreement number 305653 | EU |
| A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS EudraCT Number 2014-005355-83. NCT02456103 | PTC |
| A Phase 2, Multi-centre Double-Blinded Placebo-Controlled 3 Part Study to evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of VX661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. EudraCT-Nr.: 2011-003821-93. | Vertex |
| A Phase 3, open-label, randomized trial to evaluate the safety and efficacy of MP-376 inhalation solution (AEROQUIN™) versus Tobramycin inhalation solution (TIS) in stable cystic fibrosis patients. EudraCT-Nr.: 2010-019634-26. | MPex |
| An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis. EudraCT-Number:2009-012997-1. Dec 2010 – 2013. | Vertex |
| Europäisches Alveolarproteinose-Netzwerk (Eu-PAP-Net) | BMBF |
| A Phase 3, Randomized, Double-Blind, Placebo‑Controlled, Parallel‑Group Study to Evaluate the Efficacy and Safety of VX‑770 in Subjects with Cystic Fibrosis and the G551D Mutation. EudraCT-Number:2008-007416-15. Dec 2009 – Dec 2010. | Vertex |
| A randomized controlled study to investigate the efficacy and safety of 24 weeks of inhaled treatment with glutathione in cystic fibrosis | North American CF foundation (NACF) |
| Deutsches Netzwerk für diffus parenchymatöse Lungenerkrankungen: GOLD.net | BMBF |
| A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. EudraCT-Number: 2008-001156-43. | Boehringer Ingelheim |
| An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. EudraCT-Number:2007-006648-23. | Novartis |
| Molekulare Auswirkungen von Gendefekten im Surfactantsyntheseapparat von Typ II Pneumozyten bei interstitiellen Lungenerkrankungen (ILD) | DFG Gr970/7-3 |
| A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis. | Astraceneca |
| IGOR-basic – ex vivo study of the effects of inhaled glutathione | Mukoviszidose eV |
| Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients | Mukoviszidose eV |
| A Randomised, Open-label, Multicenter, Active controlled study of Tobramycin 100 PARI nebulised with eFlow® versus TOBI® nebulised with PARI LC PLUS® in Cystic Fibrosis Patients. | Pari GmbH |
| International multicentre study in cystic fibrosis (TIP003) | Chiron |
| Pharmacokinetics of inhaled tobramycin | Pari GmbH |
| A mass spectrometric search for serum markers of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis | Mukoviszidose eV |
| Genetik der Collektine bei CF | Mukoviszidose eV |
| Molekulare Auswirkungen von Gendefekten im Surfactantsyntheseapparat von Typ II Pneumozyten bei interstitiellen Lungenerkrankungen (ILD) | DFG Gr970/7-2 |
| Follow up, lung function | Pharmacia |
| A randomized controlled study to investigate the efficacy and safety of 24 weeks of inhaled treatment with glutathione in cystic fibrosis | North American CF foundation (NACF) |
| BI-Trial 543.45: Weltweite, randomisierte Multizenterstudie, Doppel-blind-Placebo-kontrolliert an Patienten mit Cystischer Fibrose | Böhringer Ingelheim |
| Inhaled a1-Antitrypsin in cystic fibrosis | Bayer, Central lab |
| Multicentre, randomized, two arm trial Prolastin® to investigate the optimal deposition site for inhaled Prolastin® in patients with cystic fibrosis | Bayer, Koordinationszentrum |
| AKITA-Deposition of Prolastin in central and peripheral airways | Bayer, Koordinationszentrum |
| Lungenerkrankungen unklarer Ursachen im Neugeborenen- und Kindesalter – biochemische Grundlagen | DFG Gr970/7-1 |
| Oxidative Schädigung bei chronischen respiratorischen Erkrankungen im Kindesalter | DAAD Stipendium |
| Respiratorische Erkrankungen durch gastro-ösophageale Refluxe | Projektförderung von Forschung und Lehre durch die LMU München 2002 |
| Folgestudie – Nachbeobachtung der Kohorte von Kindern und Jugendlichen mit Cystischer Fibrose | Pharmacia 2003/2004 |
| Partizipation an multizenterischer, randomisierter, doppelblinder, plazebokontrollierter Parallelgruppenstudie zur Bewertung der metabolischen und respiratorischen Wirksamkeit von Somatropin bei Kindern und Jugendlichen mit Cystischer Fibrose | Pharmacia 2001/2002 |
| Untersuchung der Surfactant Collectine und der Collectin-kodierenden Gene als potentieller Modifikatoren des Verlaufs der CF-Lungeerkrankung – Deutsch-französisches Gemeinschaftsprojekt | Mukoviszidose eV und der Vaincre la Mucoviscidose 2001 |
| Interaktionen von Surfactant Protein A und D mit Aspergillus fumigatus bei Cystischer Fibrose | Projektförderung von Forschung und Lehre durch die LMU München 2001 |
| Glutathion-Aerosol bei CF | Mukoviszidose eV |
| GSH-Deposition in der Lunge | Cf-Selbsthilfe 2001/2 |
| Chronische Atemtraktinflammation im Säuglings- und Kleinkindalter- nicht-invasive Evaluation der Behandlung mit inhalativen Steroiden | GlaxoWellcome 2001 |
| Bestimmung von Chemokin-Rezeptoren bei Atemwegserkrankungen im Kindesalter | F.-Baur-Stiftung 2000 |
| Untersuchungen der Surfactantdysfunktion mit dem capillären Surfactometer | MMW 2000 |
| Untersuchung allergischer Antikörper gegen rekombinante und natürliche Schimmelpilzallergen wie sie in der Allergie-Diagnostik verwendet werden | Sanofi/Biorad |
| Invasive und nicht-invasive Marker der Atemwegsinflammation | Vaillant-Stiftung |
| Multizenterstudie BEAT, Lavage bei CF | Mukoviszidose e.V. |
| Schlaflabor-Großgeräteantrag, 2 Plätze | DFG/Freistaat Bayern |
| Nicht-invasive Evaluation der Atemwegsinflammation im Kindesalter | F.-Baur-Stiftung 1999 |
| Lung surfactant in Cystic Fibrosis Lung Disease | Mukoviszidose e.V. |
| Surfactantaufnahme und Metabolismus (III) | DFG (Gr 970/3-3) |
| Lungensurfactant und Cystische Fibrose | W. Sander-Stiftung III |
| Multizentrische Studie zur Lavage bei Cystischer Fibrose | Roche |
Publication guidelines
All planned publications which rely on work done with data or biomaterials of the chILD-EU register should be submitted to the management committee of the chILD-EU register for coordination.
In the publications the support of the chILD-EU register must be acknowledged: "This work was supported by the European Register and Biobank on Childhood Interstitial Lung Diseases (chILD-EU register) funded by the European Commission under FP7-HEALTH-2012-INNOVATION-1, HEALTH.2012.2.4.4-2: Observational trials in rare diseases".
Authors and Contributors will disclose to readers of the contributions made to the research and to the manuscript, so that they can accept both credit and responsibility.
Authors must have satisfied all three conditions:
1. Contributed substantially to the conception and design of the study, the acquisition of data, or the analysis and interpretation.
2. Drafting or providing critical revision of the article.
3. Provided final approval of the version to be published.
All Contributors to a project must be named in a “study group” which will also be listed among the authors, in order to enhance the integrity of publication. It will contain the names of the responsible persons (physicians, study coordinators, scientists) and the respective institution. If applicable the number of completely documented subjects, and other relevant details to the project and to describe the contribution, must be indicated.
Description of individual cases, collection of similar cases, description of their data and analysis of biomaterials. Legal permission and ethical approval for these projects is covered by the patient’s informed consent and participation in the project. All Participants who contributed subjects to the chILD-EU register will be named in a publication in alphabetical order excluding first and last authorship, which are primarily determined by the degree of contribution to the project. If the limiting number of authors on a publication is not reached, the contributing Participants will be named as co-authors. If the limiting number of authors on a publication is reached, those who contributed more than 20% of the cases will be named as co-authors, the others will be named as members of the study group. Care is taken to make the members of the study group searchable in Pubmed.
Prospective observations and clinical trials. For these projects, selected by the responsible board of the chILD-EU, comprehensive clinical study protocols, all relevant and necessary legal and administrative procedures, the ethical applications and informed consent forms must be obtained before patients can be approved for the actual participation. This must be organized by the sponsor and principal investigator of the project. These projects are led by Sub-Study trial panels, consisting of a principal investigator, the national trial coordinator, the trial manager and the trial statistician. Authorship is recommended to be clarified before start of the study and may be organized similar as for the above indicated projects.
Independently of the performance of his own project, each Participant shall also contribute to the success of the chILD-EU register. Every new study will be announced on the website of the chILD-EU including title, aim, methods, and the study coordinator, as well as under clinicaltrials.gov (www.clinicaltrials.gov) and will be advertised for directly to all members of the chILD-EU.